Additionally, BTX‐9341 [397] targets CDK4/6, currently in Phase I trials in breast cancer patients (NCT06515470), while CG001419, as an NTRK‐targeting drug specifically for treating advanced solid tumors carrying NTRK alterations, is in Phase I/II clinical studies (NCT06636500). Here, CDK4 is linked to breast cancer.